Last reviewed 2026-04-23 · How we verify

North Star

North Star is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

North Star is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes, Reduction of major adverse cardiovascular events in adults with established cardiovascular disease or multiple cardiovascular risk factors.

At a glance

Mechanism of action

By inhibiting SGLT2, North Star reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is particularly beneficial for patients with type 2 diabetes, as it helps to lower blood sugar levels and improve glycemic control.

Approved indications

• Treatment of type 2 diabetes
• Reduction of major adverse cardiovascular events in adults with established cardiovascular disease or multiple cardiovascular risk factors

Common side effects

• Increased risk of diabetic ketoacidosis
• Increased risk of genital yeast infections
• Increased risk of urinary tract infections
• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Fatigue
• Headache
• Muscle cramps

Key clinical trials

• SenseToKnow Autism Screening Device Validation Study
• A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) (PHASE3)
• A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism (PHASE2)
• A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
• Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients (EARLY_PHASE1)
• School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska (NA)
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (PHASE3)
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.